ArticleGynecologic oncology2020
Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.
Article in Gynecologic oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Long-term outcomes in patients with endometrial cancer after sentinel lymph node biopsy versus lymphadenectomy alone: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Operative and Oncological Outcomes Comparing Sentinel Node Mapping and Systematic Lymphadenectomy in Endometrial Cancer Staging: Meta-Analysis With Trial Sequential Analysis.Frontiers in oncology · 2020Pooled it
- 'En bloc' peritoneal mesometrial resection (PMMR) and pelvic targeted compartmental lymphadenectomy (TCL) for management of patients with endometrial cancer - feasibility and safety study of a 'new kid on the block' in robotic surgery.World journal of surgical oncology · 2025Article
- Analysis of Sentinel Lymph Node Adoption Compared to Systematic Lymphadenectomy in Staging Early Endometrial Cancer at a Tertiary Center: An Ambispective Study.Journal of surgical oncology · 2025Article
- Therapeutic Challenges in the Management of Serous Endometrial Intraepithelial Carcinoma (SEIC).Current treatment options in oncology · 2025Review
- Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.Gynecologic oncology · 2024Article
- Oncologic Outcome of Robotic-Assisted and Laparoscopic Sentinel Node Biopsy in Endometrial Cancer.Cancers · 2023Article
- Laparoscopy with or without robotic assistance does not negatively impact long-term oncologic outcomes in patients with uterine serous carcinoma.Gynecologic oncology · 2023Article
- Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer.Journal of clinical medicine · 2022Review
- Sentinel lymph node biopsy in high-risk endometrial cancer: performance, outcomes, and future avenues.Obstetrics & gynecology science · 2022Article
- Diagnostic Accuracy of FEC-PET/CT, FDG-PET/CT, and Diffusion-Weighted MRI in Detection of Nodal Metastases in Surgically Treated Endometrial and Cervical Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Observational
- Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma.Journal of clinical medicine · 2021Review
- Standardization of lower extremity quantitative lymphedema measurements and associated patient-reported outcomes in gynecologic cancers.Gynecologic oncology · 2021Review
- Sentinel Lymph Node Mapping in Endometrial Cancer: A Comprehensive Review.Frontiers in oncology · 2021Review
- [Non endometroid endometrial cancer guidelines evaluation: A multicentric retrospective study].Bulletin du cancer · 2020Observational
- Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.Gynecologic oncology · 2020Article
- UPDATE ON SENTINEL LYMPH NODE MAPPING IN ENDOMETRIAL CANCER PATIENTS WITH A HIGH RISK FOR NODAL METASTASIS.Indian journal of gynecologic oncology · 2020Article
- Combined Adjuvant Chemotherapy and Radiation Therapy Improves Disease-Free Survival for Uterine Serous Cancer.Advances in radiation oncologyArticle
- Controversies in the Management of Early-stage Serous Endometrial Cancer.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThe objective of our study was to assess survival among patients with uterine serous carcinoma (USC) undergoing sentinel lymph node (SLN) mapping alone versus patients undergoing systematic lymphadenectomy (LND).
methodsWe retrospectively reviewed patients undergoing primary surgical treatment for newly diagnosed USC at our institution from 1/1/1996-12/31/2017. Patients were assigned to either SLN mapping alone (SLN cohort) or systematic LND without SLN mapping (LND cohort). Progression-free (PFS) and overall survival (OS) were estimated using Kaplan-Meier method, compared using Logrank test.
results245 patients were available for analysis: 79 (32.2%) underwent SLN, 166 (67.7%) LND. 132 (79.5%) in the LND cohort had paraaortic LND (PALND) versus none in the SLN cohort. Median age: 66 and 68 years in the SLN and LND cohorts, respectively (p>0.05). Proportion of stage I/II disease: 67.1% (n = 53) and 64.5% (n = 107) in the SLN and LND cohorts, respectively (p>0.05). Median follow-up: 23 (range, 1-96) and 66 months (range, 4-265) in the SLN and LND cohorts, respectively (p < 0.001). Two-year OS in stage I/II disease (n = 160, 60.1%): 96.6% (SE ± 3.4) and 89.6% (SE ± 2.2) in the SLN and LND cohorts, respectively (p = 0.8). Two-year OS in stage III disease (n = 77): 73.6% (SE ± 10.2) and 77.3% (SE ± 5.8) in the SLN and LND cohorts, respectively (p = 0.8).
conclusionsSLN mapping alone and systematic LND yielded similar survival outcomes in stage I-III USC. In our practice, the SLN algorithm has replaced systematic LND as the primary staging modality in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.